Assessment of Lymphoid Molecular Clonality in Canine Thymoma

Vessieres, Florence; Rasotto, Roberta; Peters, Iain R.; Villiers, Elizabeth; Berlato, Davide; Cian, Francesco

doi:10.1016/j.jcpa.2017.12.001

Cited by 5 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PARR may also help to differentiate lymphoma and non-lymphoma. To the best of our knowledge no specific papers on the use of PARR for differentiating lymphoma vs. thymoma in cats are available, but results of PARR analysis in a cohort of 13 dogs with thymoma was recently published and found a polyclonal result in 12 cases while T-cell clonality was detected in one case (19). In the cat, PARR and FC were used to confirm the origin from an ectopic thymoma in a cat with cervical mass from ectopic thymoma (20).…”

Section: Discussionmentioning

confidence: 99%

Flow Cytometric Analysis of Mediastinal Masses in Cats: A Retrospective Study

Bernardi

Martini

Perfetto³

et al. 2020

Front. Vet. Sci.

View full text Add to dashboard Cite

Mediastinal masses occur in dogs and cats and are often investigated with cytology. However, discrimination between the two most common lesions (thymoma and lymphoma) may be challenging, especially when small/medium lymphocytes represent the prevalent population. The aim of the present study is to describe the flow cytometric aspects of mediastinal masses in cats and to assess the ability of flow cytometry (FC) to differentiate lymphoma from non-lymphomatous lesions. We retrospectively describe FC features of fine needle aspiration cytology from cats with mediastinal masses. Cases were grouped in lymphoma and non-lymphoma based on results of cytology, histopathology, PCR for antigen receptor rearrangement (PARR), clinical presentation, and follow-up. Scatter properties, positivities to CD5, CD4, CD8, CD21, CD18, and their co-expressions were recorded using a multicolour approach. Twenty cats were included, 12 lymphomas and eight non-lymphomatous cases. Forward scatter (FSC) of lymphoid cells was higher in the lymphoma group. Double positive CD4+CD8+ T-cells were the dominant population in eight out of 12 lymphomas, whereas non-lymphomatous lesions showed no dominant lymphoid population in five out of eight cases. Unlike dogs, the high prevalence of CD4+CD8+ lymphomas in cats it makes difficult to differentiate lymphoma from non-lymphomatous lesions using FC alone. FC may add interesting information to refine diagnosis in some cases, but PARR and histopathology remain mandatory to solve differential in case of expansion of small-medium sized double positive lymphoid cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Flow Cytometric Analysis of Mediastinal Masses in Cats: A Retrospective Study

Bernardi

Martini

Perfetto³

et al. 2020

Front. Vet. Sci.

View full text Add to dashboard Cite

show abstract

“…A common clinical problem is the differentiation of reactive and neoplastic lymphocyte populations; espe-509 British Small Animal Veterinary Association cially in settings in which collecting tissue biopsies is challenging due to cost or morbidity. Clinical uses include aiding in the differentiation of follicular lymphomas and inflammation, differentiating chronic enteropathies from lymphoma and separating thymoma from mediastinal lymphoma (Burnett et al 2003, Vessieres et al 2018. A significant strength of PARR is that it can often be performed on previously collected FNA and biopsy samples which have yielded an equivocal result thus obviating the need for further sampling procedures.…”

Section: Diagnosis Of Lymphoma Using Parrmentioning

confidence: 99%

“…Cytological, formalin-fixed paraffin-embedded and fresh tissue preparations can be used for PARR (Burnett et al 2003, Vessieres et al 2018. DNA extracted from a sample containing lymphocytes is used as a template for PCR amplification of part of the T cell or B cell receptor.…”

Section: Diagnosis Of Lymphoma Using Parrmentioning

confidence: 99%

“…As highlighted above, several laboratories have developed a variety of PARR methodologies and as yet there is no broadly (Goto-Koshino et al 2015, Waugh et al 2016, Vessieres et al 2018) and up to 98% (Gentilini et al 2009. In one study, the sensitivity was lower in intestinal compared to lymph node assessments (Goto-Koshino et al 2015).…”

Section: Diagnosis Of Lymphoma Using Parrmentioning

confidence: 99%

“…2017, Vessieres et al . 2018). A significant strength of PARR is that it can often be performed on previously collected FNA and biopsy samples which have yielded an equivocal result thus obviating the need for further sampling procedures.…”

Section: What Is Available In the Clinic Now?mentioning

confidence: 99%

See 2 more Smart Citations

Molecular pathology in the cancer clinic – where are we now and where are we headed?

Guillén

Smallwood

Killick

2021

J of Small Animal Practice

View full text Add to dashboard Cite

Molecular pathology is a developing sub-microscopic discipline of pathology that studies the effects of molecular variations and mutations on disease processes. The ultimate goal of molecular pathology in cancer is to predict risk, facilitate diagnosis and improve prognostication based on a complete understanding of the biological impact of specific molecular variations, mutations and dysregulations. This knowledge will provide the basis for customised cancer treatment, so-called precision medicine. Rapid developments in genomics have placed this field at the forefront of clinical molecular pathology and there are already a number of well-established genetic tests available for clinical use including PCR of antigen receptor rearrangement and KIT mutational analysis. Moving beyond tests assessing a single gene, there are significant research efforts utilising genomics to predict cancer risk, forecast aggressive behaviour and identify druggable mutations and therapeutic biomarkers. Researchers are also investigating the use of circulating cells and nucleic acid for clinically useful low morbidity genomic assessments. If we are to realise the full potential of molecular pathology and precision medicine there are a number of challenges to overcome. These include developing our understanding of the underlying biology (in particular intra-tumoural heterogeneity), methodological standardisation of assays, provision of adequate infrastructure and production of novel therapeutics backed by high-quality clinical data supporting the precision medicine approach. The era of molecular pathology holds the potential to revolutionise veterinary cancer care, but its impact on clinical practice will depend upon the extent to which the inherent challenges can be overcome.

show abstract

Molecular Clonality Testing

Seelig¹,

Avery²

2020

Veterinary Cytology

View full text Add to dashboard Cite

Assessment of Lymphoid Molecular Clonality in Canine Thymoma

Cited by 5 publications

References 11 publications

Flow Cytometric Analysis of Mediastinal Masses in Cats: A Retrospective Study

Flow Cytometric Analysis of Mediastinal Masses in Cats: A Retrospective Study

Molecular pathology in the cancer clinic – where are we now and where are we headed?

Molecular Clonality Testing

Contact Info

Product

Resources

About